In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells

Cancer Gene Therapy

Volumn 9, Issue 3, 2002, Pages 282-288

  Grangeon, Cendrine ^a   Cormary, Carine ^a   Douin Echinard, Vickorine ^a   Favre, Gilles ^a   Couderc, Bettina ^a   Tilkin Mariamé, Anne Fraņoise ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Animal models; CD154; Immunotherapy; Mammary adenocarcinoma; Melanoma

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DNA MODIFICATION; FLOW CYTOMETRY; IMMUNOTHERAPY; LYMPHOCYTE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0036195217     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700439     Document Type: Article

References (22)

1. T cell defined tumor antigens
2. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells
3. Constitutive expression of B7-1 (CD80) on mouse keratinocytes does not prevent development of chemically induced skin papillomas and carcinomas
4. Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70
5. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response
6. CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity
7. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes
8. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or - dependent stimuli
9. Dendritic cells: Therapeutic potentials
10. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
11. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration
12. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1associated cytokines
13. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
14. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
15. Immunogenicity of tumor peptides: Importance of peptide length and stability of peptide/MHC class II complex
16. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
17. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status
18. + IFN-gamma-producing T cells from tumor-infiltrating lymphocytes
19. Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism
20. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines
21. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors
22. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells